These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 10415067)
1. Evidence for the involvement of CD44 in endothelial cell injury and induction of vascular leak syndrome by IL-2. Rafi-Janajreh AQ; Chen D; Schmits R; Mak TW; Grayson RL; Sponenberg DP; Nagarkatti M; Nagarkatti PS J Immunol; 1999 Aug; 163(3):1619-27. PubMed ID: 10415067 [TBL] [Abstract][Full Text] [Related]
2. Evidence for the involvement of Fas ligand and perforin in the induction of vascular leak syndrome. Rafi AQ; Zeytun A; Bradley MJ; Sponenberg DP; Grayson RL; Nagarkatti M; Nagarkatti PS J Immunol; 1998 Sep; 161(6):3077-86. PubMed ID: 9743374 [TBL] [Abstract][Full Text] [Related]
3. Blockade of hyaluronan inhibits IL-2-induced vascular leak syndrome and maintains effectiveness of IL-2 treatment for metastatic melanoma. Guan H; Nagarkatti PS; Nagarkatti M J Immunol; 2007 Sep; 179(6):3715-23. PubMed ID: 17785808 [TBL] [Abstract][Full Text] [Related]
4. Cooperation between CD44 and LFA-1/CD11a adhesion receptors in lymphokine-activated killer cell cytotoxicity. Matsumoto G; Nghiem MP; Nozaki N; Schmits R; Penninger JM J Immunol; 1998 Jun; 160(12):5781-9. PubMed ID: 9637488 [TBL] [Abstract][Full Text] [Related]
5. Regulation of interleukin-2-induced vascular leak syndrome by targeting CD44 using hyaluronic acid and anti-CD44 antibodies. Mustafa A; McKallip RJ; Fisher M; Duncan R; Nagarkatti PS; Nagarkatti M J Immunother; 2002; 25(6):476-88. PubMed ID: 12439345 [TBL] [Abstract][Full Text] [Related]
6. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells. Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733 [TBL] [Abstract][Full Text] [Related]
7. Constitutive expression of IL-2Rbeta chain and its effects on IL-2-induced vascular leak syndrome. Assier E; Jullien V; Lefort J; Moreau JL; Vargaftig BB; Lapa e Silva JR; Thèze J Cytokine; 2005 Dec; 32(6):280-6. PubMed ID: 16378732 [TBL] [Abstract][Full Text] [Related]
8. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. Rosenstein M; Ettinghausen SE; Rosenberg SA J Immunol; 1986 Sep; 137(5):1735-42. PubMed ID: 3528289 [TBL] [Abstract][Full Text] [Related]
9. Systemic administration of recombinant interleukin 2 stimulates in vivo lymphoid cell proliferation in tissues. Ettinghausen SE; Lipford EH; Mulé JJ; Rosenberg SA J Immunol; 1985 Aug; 135(2):1488-97. PubMed ID: 3891854 [TBL] [Abstract][Full Text] [Related]
10. Inducible nitric oxide synthase (iNOS) is not required for IL-2-induced hypotension and vascular leak syndrome in mice. Kondapaneni M; McGregor JR; Salvemini D; Laubach VE; Samlowski WE J Immunother; 2008 May; 31(4):325-33. PubMed ID: 18391763 [TBL] [Abstract][Full Text] [Related]
11. Lymphokine activated killer (LAK) cell-mediated endothelial injury: a mechanism for capillary leak syndrome in patients treated with LAK cells and interleukin-2. Kotasek D; Vercellotti GM; Ochoa AC; Bach FH; Jacob HS Trans Assoc Am Physicians; 1987; 100():21-7. PubMed ID: 3502662 [TBL] [Abstract][Full Text] [Related]
12. Targeted deletion of CD44v7 exon leads to decreased endothelial cell injury but not tumor cell killing mediated by interleukin-2-activated cytolytic lymphocytes. McKallip RJ; Fisher M; Do Y; Szakal AK; Gunthert U; Nagarkatti PS; Nagarkatti M J Biol Chem; 2003 Oct; 278(44):43818-30. PubMed ID: 12904302 [TBL] [Abstract][Full Text] [Related]
13. Role of CD4(+)CD25(+) T regulatory cells in IL-2-induced vascular leak. Melencio L; McKallip RJ; Guan H; Ramakrishnan R; Jain R; Nagarkatti PS; Nagarkatti M Int Immunol; 2006 Oct; 18(10):1461-71. PubMed ID: 16914509 [TBL] [Abstract][Full Text] [Related]
14. Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells. Ettinghausen SE; Lipford EH; Mulé JJ; Rosenberg SA J Immunol; 1985 Nov; 135(5):3623-35. PubMed ID: 3900213 [TBL] [Abstract][Full Text] [Related]
15. Regulation of cell morphology in B lymphocytes by IL-4: evidence for induced cytoskeletal changes. Davey EJ; Thyberg J; Conrad DH; Severinson E J Immunol; 1998 Jun; 160(11):5366-73. PubMed ID: 9605136 [TBL] [Abstract][Full Text] [Related]
16. Decrease in interleukin 2-induced vascular leakage in the lungs of mice by administration of recombinant interleukin 1 alpha in vivo. Puri RK; Travis WD; Rosenberg SA Cancer Res; 1989 Feb; 49(4):969-76. PubMed ID: 2783561 [TBL] [Abstract][Full Text] [Related]
17. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction. Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399 [TBL] [Abstract][Full Text] [Related]
18. CD44 disruption prevents degeneration of the capillary network in obstructive nephropathy via reduction of TGF-beta1-induced apoptosis. Rouschop KM; Claessen N; Pals ST; Weening JJ; Florquin S J Am Soc Nephrol; 2006 Mar; 17(3):746-53. PubMed ID: 16452493 [TBL] [Abstract][Full Text] [Related]
19. Mechanism of cultured endothelial injury induced by lymphokine-activated killer cells. Kotasek D; Vercellotti GM; Ochoa AC; Bach FH; White JG; Jacob HS Cancer Res; 1988 Oct; 48(19):5528-32. PubMed ID: 3262010 [TBL] [Abstract][Full Text] [Related]
20. IL-4-transduced tumor cell vaccine induces immunoregulatory type 2 CD8 T lymphocytes that cure lung metastases upon adoptive transfer. Rodolfo M; Zilocchi C; Accornero P; Cappetti B; Arioli I; Colombo MP J Immunol; 1999 Aug; 163(4):1923-8. PubMed ID: 10438927 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]